This Saturday, Biocartis is present at the investor event VFB Happening, organized by the Flemish Federation of Investors, on the topic Technology.
Their CEO Hilde Windels will speak about Biocartis' continuous technological innovations, and commitment to give all patients access to treatments with the best possible health outcome, through faster, easier and more accurate (cancer) diagnostics.
Feel free to visit Biocartis at booth n° 3001 - address: Kinepolis Event Centre Antwerpen, Groenendaallaan 394, 2030 Antwerp, Belgium.
For more information and registration, please visit the VFB website.
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis’ proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis launched the Idylla™ platform in September 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Today, Biocartis offers eight oncology tests and two infectious disease tests.